Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months

ClinicalTrials.gov ID: NCT00806546

Public ClinicalTrials.gov record NCT00806546. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will use an open-label design to evaluate the safety of NP101. Adult subjects who meet the enrollment criteria will be treated with NP101 (sumatriptan succinate iontophoretic transdermal patch) for acute migraine attacks over a 12 month period.

Study identification

NCT ID
NCT00806546
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
NuPathe Inc.
Industry
Enrollment
514 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2009
Primary completion
Apr 30, 2011
Completion
Apr 30, 2011
Last update posted
Feb 3, 2016

2009 – 2011

United States locations

U.S. sites
31
U.S. states
17
U.S. cities
31
Facility City State ZIP Site status
Not listed Phoenix Arizona
Not listed Scottsdale Arizona
Not listed Irvine California
Not listed Newport Beach California
Not listed San Francisco California
Not listed Santa Monica California
Not listed Walnut Creek California
Not listed Fairfield Connecticut
Not listed Hallandale Florida
Not listed Ocala Florida
Not listed Sunrise Florida
Not listed Atlanta Georgia
Not listed Decatur Georgia
Not listed Savannah Georgia
Not listed Crestview Hills Kentucky
Not listed Ann Arbor Michigan
Not listed St Louis Missouri
Not listed Mount Vernon New York
Not listed Plainview New York
Not listed Greensboro North Carolina
Not listed Cincinnati Ohio
Not listed Cleveland Ohio
Not listed Oklahoma City Oklahoma
Not listed Philadelphia Pennsylvania
Not listed Pittsburgh Pennsylvania
Not listed Clarksville Tennessee
Not listed Dallas Texas
Not listed San Antonio Texas
Not listed Alexandria Virginia
Not listed Virginia Beach Virginia
Not listed Seattle Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00806546, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 3, 2016 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00806546 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →